The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus

Renal Failure

Volumn 26, Issue 6, 2004, Pages 597-605

  Gunduz, Zubeyde ^a   Canoz, Ozlem ^a   Per, Huseyin ^a   Dusunsel, Ruhan ^a   Poyrazoglu, M Hakan ^a   Tez, Coskun ^a   Saraymen, Recep ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Diabetic renal growth; Epidermal growth factor receptor; Nitric oxide; Pentoxifylline; Streptozotocin induced diabetes mellitus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NITRIC OXIDE; PENTOXIFYLLINE; PROTEIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRY WEIGHT; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY DEVELOPMENT; KIDNEY MASS; KIDNEY PARENCHYMA; KIDNEY SIZE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT;

ANIMALS; BIOPSY, NEEDLE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; MALE; PENTOXIFYLLINE; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; STREPTOZOCIN;

EID: 9644295631     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200038329     Document Type: Article

References (44)

1. Wolf, G.; Ziyadeh, F.N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999, 56, 393-405.
2. Burns, K.D. Angiotensin II and its receptors in the diabetic kidney. Am. J. Kidney Dis. 2000, 36, 449-467.
3. Bertoluci, M.C.; Schmid, H.; Lachat, J.J.; Coimbra, T.M. Transforming growth factor-beta in the development of rat diabetic nephropathy. A 10-month study with insulin-treated rats. Nephron 1996, 74, 189-196.
4. Flyujberg, A.; Grønbæk, H.; Bak, M.; Nielsen, B.; Christiansen, T.; Hill, C.; Logan, A.; Ørskov, H. Diabetic kidney disease: the role of growth factors. Nephrol. Dial. Transplant. 1998, 13, 1104-1107.
5. Guh, J.Y.; Lai, Y.H.; Shin, S.J.; Chuang, L.Y.; Tsai, J.H. Epidermal growth factor in renal hypertrophy in streptozotocin-diabetic rats. Nephron 1991, 56, 641-647.
6. Muchaneta-Kubara, E.G.; Sayed-Ahmed, N.; Besbas, N.; Zhang, G.; Cope, G.H.; El Nahas, A.M. Experimental diabetic renal growth: role of growth hormone and insulin-like growth factor-I. Nephrol. Dial. Transplant. 1994, 9, 1395-1401.
7. Ha, H.; Kim, K.H. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res. Clin. Pract. 1999, 45, 147-151.
8. Suzuki, D.; Miyata, T.; Saotome, N.; Horie, K.; Inag, R.; Yasuda, Y.; Uchida, K.; Izuhara, Y.; Yegame, M.; Sakai, H.; Kurokawa, K. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J. Am. Soc. Nephrol. 1999, 10, 822-832.
9. Samlaska, C.P.; Winfield, E.A. Pentoxifylline. J. Am. Acad. Dermatol. 1994, 30, 603-621.
10. Strutz, F.; Heeg, M.; Kochsiek, T.; Siemers, G.; Zeisberg, M.; Muller, G.A. Effects of pentoxifylline, pentifylline and γ-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol. Dial. Transplant. 2000, 15, 1535-1546.
11. Navarro, J.F.; Mora, C.; Rivero, A.; Gallego, E.; Chahin, J.; Macía, M.; Méndez, M.L.; García, J. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 1999, 33, 458-463.
12. Tripathi, K.; Prakas, J.; Appaiha, D.; Srivastava, P.K. Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 1993, 64, 641-642.
13. Lowry, O.H.; Rosebrough, N.I.; Farr, A.L.; Randall, R.J. Protein measurement with the folin-phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
14. Davidge, S.T.; Christopher, P.S. Urine but not plasma nitric oxide metabolites are decreased in women with preeclampsia. Am. J. Obstet. Gynecol. 1996, 174, 1008-1013.
15. Sugimoto, H.; Shikata, K.; Matsuda, M.; Kushira, M.; Hayashi, Y.; Hiragushi, K.; Wada, J.; Makino, H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998, 41, 1426-1434.
16. Sayed-Ahmed, N.; Besbas, N.; Mundy, J.; Muchaneta-Kubara, A.; Cope, G.; Pearson, C.; El Nahas, M. Upregulation of epidermal growth factor and its receptor in the kidneys of rats with streptozotocin-induced diabetes. Exp. Nephrol. 1996, 4, 330-339.
17. Di Landro, D.; Catalano, C.; Lambertini, D.; Bordin, V.; Fabbian, F.; Naso, A.; Rmognoli, G.F. The effect of metabolic control on development and progression of diabetic nephropathy. Nephrol. Dial. Transplant. 1998, 13 (Suppl 8), 35-43.
18. Zatz, R.; Dunn, B.R.; Meyer, T.W.; Anderson, S.; Rennke, H.G.; Brenner, B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 1986, 77, 1925-1930.
19. Ahmad, J.; Siddiqui, M.A.; Ahmad, H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997, 20, 1576-1581.
20. Remuzzi, A.; Perico, N.; Amuchastegui, C.S.; Malanchini, B.; Mazerska, M.; Battaglia, C.; Bertani, T.; Remuzzi, G. Short and long-term effects of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. Nephrol. 1993, 4, 40-49.
21. Remuzzi, A.; Fassi, A.; Sangalli, F.; Malanchini, B.; Mohamed, E.I.; Bertani, T.; Remuzzi, G. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. Exp. Nephrol. 1998, 6, 28-38.
22. Solerte, S.B.; Fioravanti, M.; Bozzetti, A.; Schifine, N.; Patti, A.L.; Fedele, P.; Viola, C.; Ferrari, E. Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria, results of a short-term randomized study. Acta Diabetol. Lat. 1986, 23, 171-177.
23. Solerte, S.B.; Fioravanti, M.; Patti, A.L.; Schifino, N.; Zanoletti, M.G.; Inglese, V.; Ferrari, E. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol. Lat. 1987, 24, 229-239.
24. Guerrero-Romero, F.; Rodriguez-Maron, M.; Paniagua-Sierra, J.R.; Garcia-Bulnes, G.; Salas-Ramirez, M.; Amato, D. Pentoxifylline reduces proteinuria in insulin dependent and non insulin-dependent diabetic patients. Clin. Nephrol. 1995, 43, 116-121.
25. Angielski, S.; Jakubowski, Z.; Pawelczyk, T.; Piec, G.; Redlak, M. Renal handling and metabolism of adenosine in diabetic rats. Contrib. Nephrol. 1989, 73, 52-56.
26. Rasch, R.; Dorup, J. Quantitative morphology of the rat kidney during diabetes mellitus and insulin treatment. Diabetologia 1997, 40, 802-809.
27. Ferrari, E.; Fiovaranti, M.; Patti, A.L.; Viola, C.; Solerte, J.B. Effects of long-term treatment (4 years) with pentoxifylline on hemorheological changes and vascular complications in diabetic patients. Pharmatherapetica 1987, 5, 26-39.
28. Sayer-Hansen, K. Renal hypertrophy in streptozotocin-diabetic rats. Clin. Sci. Mol. Med. 1976, 51, 551-555.
29. Sayer-Hansen, K. Renal hypertrophy in experimental diabetes. Kidney Int. 1983, 23, 643-646.
30. Gilbert, R.E.; Cox, A.; Mc Nally, P.G.; Wull, L.; Dziadek, M.; Cooper, M.E.; Jerums, G. Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 1997, 40, 778-785.
31. Lee, D.C.; Chan, K.W.; Chan, S.Y. Expression of transforming growth factor alpha and epidermal growth factor in adult polycystic kidney disease. J. Urol. 1998, 159, 291-296.
32. Chen, Y.M.; Chien, C.T.; Hu-Tsai, M.I.; Wu, K.D.; Tsai, C.C.; Wu, M.S.; Tsai, T.J. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999, 56, 932-943.
33. Komers, R.; Allen, T.J.; Cooper, M.E. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994, 43, 1190-1197.
34. Keynan, S.; Hirshberg, B.; Levin-Iaina, N.; Wexler, I.D.; Dahan, R.; Reinhartz, E.; Ovadia, H.; Wollman, Y.; Chernihovskey, T.; Iaina, A.; Raz, I. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int. 2000, 58, 740-747.
35. Chiarelli, F.; Cipollone, F.; Romana, F.; Tumini, S.; Constantini, F.; di Ricco, L.; Pamilia, M.; Pierdomenica, S.D.; Marini, M.; Caccurullo, F.; Mezzetti, A. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 2000, 49, 1258-1263.
36. Veelken, R.; Hilgers, K.F.; Hartner, A.; Haas, A.; Bohmer, K.P.; Sterzel, R.B. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 2000, 11, 71-79.
37. Choi, K.C.; Lee, S.C.; Kim, S.W.; Kim, N.H.; Lee, J.U.; Kang, Y.J. Role of nitric oxide in the pathogenesis of diabetic nephropathy in streptozotocin-induced diabetic rats. Korean J. Intern. Med. 1999, 14, 32-41.
38. Trachtman, H.; Futterweit, S.; Crimmins, D.L. High glucose inhibits nitric oxide production in cultured rat mesangial cells. J. Am. Soc. Nephrol. 1997, 8, 1276-1282.
39. Muhl, H.; Chang, J.H.; Huwiler, A.; Bossmann, M.; Paulukat, J.; Ninic, R.; Nold, M.; Hellmuth, M.; Pfeilschifter, J. Nitric oxide augments release of chemokines from monocytic U 937 cells: modulation by anti-inflammatory pathways. Free Radic. Biol. Med. 2000, 29, 969-980.
40. Samardzic, T.; Stosic-Grujicic, S.; Maksimovic, D.; Jankovic, V.; Trajkovic, V. Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L 929 fibrosarcoma cell line. Immunol. Lett. 2000, 71, 149-155.
41. Weinberg, J.B.; Mason, S.N.; Wortham, T.S. Inhibition of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) messenger RNA (mRNA) expression in HL-60 leukemia cells by pentoxifylline and dexamethasone: dissociation of acivicin-induced monocytoid differentiation. Blood 1992, 79, 3337-3343.
42. Koo, D.J.; Yoo, P.; Cioffi, W.G.; Bland, K.I.; Chaudry, I.H.; Wang, P. Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J. Surg. Res. 2000, 91, 70-76.
43. Krakauer, T. Pentoxifylline inhibits ICAM-I expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells. Immunopharmacology 2000, 46, 253-261.
44. Lauterbach, R.; Pawlik, D.; Kowalczyk, D.; Ksyncinski, W.; Helwich, E.; Zembala, M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit. Care Med. 1999, 27, 807-814.